Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$12.07 - $18.46 $2 Million - $3.06 Million
-165,878 Reduced 89.71%
19,029 $280,000
Q3 2023

Nov 14, 2023

BUY
$18.08 - $23.45 $1.55 Million - $2.01 Million
85,567 Added 86.14%
184,907 $3.39 Million
Q2 2023

Aug 14, 2023

BUY
$20.98 - $31.42 $651,680 - $975,968
31,062 Added 45.49%
99,340 $2.14 Million
Q1 2023

May 15, 2023

BUY
$27.71 - $40.93 $627,243 - $926,491
22,636 Added 49.59%
68,278 $2 Million
Q4 2022

Feb 14, 2023

BUY
$29.75 - $39.26 $1.36 Million - $1.79 Million
45,642 New
45,642 $1.69 Million

Others Institutions Holding AMLX

About Amylyx Pharmaceuticals, Inc.


  • Ticker AMLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,533,200
  • Market Cap $290M
  • Description
  • Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...
More about AMLX
Track This Portfolio

Track J. Goldman & CO LP Portfolio

Follow J. Goldman & CO LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

News

Stay updated on J. Goldman & CO LP with notifications on news.